• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»PTC Therapeutics

What the FDA decision on PTC Therapeutics’ Translarna reveals about Duchenne muscular dystrophy drug approvals

By Pallavi Madhiraju on February 13, 2026   Pharma & Biotech  

What the FDA decision on PTC Therapeutics’ Translarna reveals about Duchenne muscular dystrophy drug approvals

PTC Therapeutics has withdrawn its U.S. filing for Translarna. Find out what this means for Duchenne drug development and FDA expectations.

PTC Therapeutics receives Japanese approval for Sephience in full-spectrum PKU

By Venkatesh B on December 22, 2025   Pharma & Biotech  

PTC Therapeutics receives Japanese approval for Sephience in full-spectrum PKU

Japan approves Sephience for PKU across all ages. Find out what this means for PTC Therapeutics’ global rare disease expansion strategy.

Recent Posts

  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes